News

At-home Gait Monitor May Track Progression, Treatment Response

Continuously monitoring the gait of Parkinson’s disease patients in their homes using a wireless device is feasible and may provide more sensitive measurements of disease progression and treatment response, according to a new study. The device, which monitors fluctuations in motor function by tracking gait speed, may improve disease…

MJFF and Edmond J. Safra Foundation Expand Network

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced it will expand the number and reach of Parkinson’s disease clinician-researchers around the world, in partnership with the Edmond J. Safra Foundation. The Edmond J. Safra Fellowship in Movement Disorders aims to fund medical centers to…

Oral GT-02287 Improves Fine Motor Skills in Mice

Gain Therapeutics’ GT-02287, an oral candidate therapy for Parkinson’s disease, led to dose-dependent improvements in the health of nerve cells and fine motor skills in mice. These findings, presented recently as a poster at the International Congress of Parkinson’s Disease and Movement Disorders 2022 in Madrid, add to…

Raised Disease Risk Tied to Early, Midlife Hospital-treated Infections

A new study suggests that infections requiring specialty hospital care are associated with an increased risk of developing Parkinson’s disease later in life. An increased risk also was observed for Alzheimer’s disease, but not for amyotrophic lateral sclerosis (ALS). “Hospital-treated infections, especially in early- and mid-life, were associated with…

Turning Words Into Actions May Improve Memory

Acting out a word or phrase may help people keep memory of it — a phenomenon called the enactment effect — and this also may hold true for those with poor motor control due to Parkinson’s disease, according to a review study. “Our meta-analysis found that even Parkinson’s disease…

Neuron23, QIAGEN Developing Test to Find Patients for LRRK2 Inhibitor

Neuron23 and QIAGEN have joined forces to develop a companion test to predict the response of patients to Neuron23’s experimental treatment for Parkinson’s disease, called NEU-723. “QIAGEN’s blood-based test will help to identify patients with Parkinson’s disease who are likely to respond to Neuron23’s LRRK2 inhibitor,” Nancy Stagliano,…

Phase 1/2 Trial Supports Ketamine for Levodopa-induced Dyskinesia

New trial data suggest that low-dose ketamine — which does not induce anesthesia — may be a potential treatment for levodopa-induced dyskinesia, or involuntary movements, in Parkinson’s disease. “Ketamine was safe [and] well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias,” PharmaTher Holdings, the Canadian-based…